{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:57:02Z","timestamp":1784152622691,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,3]]},"DOI":"10.7759\/cureus.9536","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T20:02:31Z","timestamp":1596484951000},"source":"Crossref","is-referenced-by-count":20,"title":["Neuropsychiatric Effects of Antiviral Drugs"],"prefix":"10.7759","author":[{"given":"Nicholas","family":"Zareifopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lagadinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Karela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania","family":"Kyriakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Velissaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3827-4","article-title":"Neuropsychiatric events in an adult patient with influenza a (H3N2) treated with oseltamivir (Tamiflu): a case report","volume":"19","author":"Chen R","year":"2019","unstructured":"Chen R, Fang Z, Huang Y. Neuropsychiatric events in an adult patient with influenza a (H3N2) treated with oseltamivir (Tamiflu): a case report. BMC Infect Dis. 2019, 19:224. 10.1186\/s12879-019-3827-4","journal-title":"BMC Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky445","article-title":"Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study","volume":"74","author":"Kang H-R","year":"2019","unstructured":"Kang H-R, Lee E-K, Kim WJ, Shin J-Y. Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study. J Antimicrob Chemother. 2019, 74:453-461. 10.1093\/jac\/dky445","journal-title":"J Antimicrob Chemother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12629","article-title":"The mechanisms of sudden-onset type adverse reactions to oseltamivir","volume":"135","author":"Hama R","year":"2017","unstructured":"Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol Scand. 2017, 135:148-160. 10.1111\/ane.12629","journal-title":"Acta Neurol Scand"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00253","article-title":"Analysis of neuropsychiatric adverse events in patients treated with oseltamivir in spontaneous adverse event reports","volume":"38","author":"Ueda N","year":"2015","unstructured":"Ueda N, Umetsu R, Abe J, et al.. Analysis of neuropsychiatric adverse events in patients treated with oseltamivir in spontaneous adverse event reports. Biol Pharm Bull. 2015, 38:1638-1644. 10.1248\/bpb.b15-00253","journal-title":"Biol Pharm Bull"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl067","article-title":"The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment","volume":"57","author":"Hellden A","year":"2006","unstructured":"Hellden A, Lycke J, Vander T, Svensson J-O, Odar-Cederlof I, Stahle L. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother. 2006, 57:945-949. 10.1093\/jac\/dkl067","journal-title":"J Antimicrob Chemother"},{"key":"ref6","article-title":"Neuropsychiatric manifestations in a patient undergoing hemodialysis caused by treatment with oral acyclovir","volume":"15","author":"Skhiri H","year":"2004","unstructured":"Skhiri H, Achour A, Skhiri S, et al.. Neuropsychiatric manifestations in a patient undergoing hemodialysis caused by treatment with oral acyclovir. Saudi J Kidney Dis Transpl. 2004, 15:50-52.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02527.x","article-title":"Valacyclovir neurotoxicity: clinical experience and review of the literature","volume":"16","author":"Asahi T","year":"2009","unstructured":"Asahi T, Tsutsui M, Wakasugi M, et al.. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur J Neurol. 2009, 16:457-460. 10.1111\/j.1468-1331.2008.02527.x","journal-title":"Eur J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.50.3.293","article-title":"Valacyclovir-induced psychosis and manic symptoms in an adolescent young woman with genital herpes simplex","volume":"50","author":"Aslam SP","year":"2009","unstructured":"Aslam SP, Carroll KA, Naz B, Alao AO. Valacyclovir-induced psychosis and manic symptoms in an adolescent young woman with genital herpes simplex. Psychosomatics. 2009, 50:293-296. 10.1176\/appi.psy.50.3.293","journal-title":"Psychosomatics"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-5-1130","article-title":"Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism","volume":"72","author":"Jacobson MA","year":"1991","unstructured":"Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab. 1991, 72:1130-1135. 10.1210\/jcem-72-5-1130","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i5.227","article-title":"Adverse effects of oral antiviral therapy in chronic hepatitis B","volume":"9","author":"Kayaaslan B","year":"2017","unstructured":"Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017, 9:227-241. 10.4254\/wjh.v9.i5.227","journal-title":"World J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3051","article-title":"Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study","volume":"21","author":"Kamara DA","year":"2016","unstructured":"Kamara DA, Smith C, Ryom L, et al.. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. Antivir Ther. 2016, 21:495-506. 10.3851\/IMP3051","journal-title":"Antivir Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000172367.71932.61","article-title":"Acute dystonia induced by lamivudine","volume":"28","author":"Song X","year":"2005","unstructured":"Song X, Hu Z, Zhang H. Acute dystonia induced by lamivudine. Clin Neuropharmacol. 2005, 28:193-194. 10.1097\/01.wnf.0000172367.71932.61","journal-title":"Clin Neuropharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6255","article-title":"Psychiatric side effects of pegylated interferon-alpha and ribavirin therapy in Iranian patients with chronic hepatitis C: a meta-analysis","volume":"16","author":"Davoodi L","year":"2018","unstructured":"Davoodi L, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas MR, Mousavi T. Psychiatric side effects of pegylated interferon-alpha and ribavirin therapy in Iranian patients with chronic hepatitis C: a meta-analysis. Exp Ther Med. 2018, 16:971-978. 10.3892\/etm.2018.6255","journal-title":"Exp Ther Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-1013-1","article-title":"A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety","volume":"19","author":"Sakamaki A","year":"2019","unstructured":"Sakamaki A, Kamimura K, Fukui N, et al.. A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. BMC Gastroenterol. 2019, 19:85. 10.1186\/s12876-019-1013-1","journal-title":"BMC Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000051384","article-title":"Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C","volume":"18","author":"Fontana RJ","year":"2000","unstructured":"Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis. 2000, 18:107-116. 10.1159\/000051384","journal-title":"Dig Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6481","article-title":"Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection","volume":"16","author":"Takeda K","year":"2018","unstructured":"Takeda K, Noguchi R, Namisaki T, et al.. Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. Exp Ther Med. 2018, 16:2743-2750. 10.3892\/etm.2018.6481","journal-title":"Exp Ther Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000183","article-title":"Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study","volume":"4","author":"Volpato S","year":"2017","unstructured":"Volpato S, Montagnese S, Zanetto A, et al.. Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study. BMJ Open Gastroenterol. 2017, 4:e000183. 10.1136\/bmjgast-2017-000183","journal-title":"BMJ Open Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2014.00007","article-title":"Patient characteristics, safety, and tolerability with telaprevir treatment for HCV in the clinic: a retrospective, multicenter study","volume":"2","author":"Flamm SL","year":"2014","unstructured":"Flamm SL, Pockros PJ, Bengtsson L, Friedman M. Patient characteristics, safety, and tolerability with telaprevir treatment for HCV in the clinic: a retrospective, multicenter study. J Clin Transl Hepatol. 2014, 2:65-73. 10.14218\/JCTH.2014.00007","journal-title":"J Clin Transl Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12300","article-title":"Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2\/3 clinical trials","volume":"34","author":"Manns MP","year":"2014","unstructured":"Manns MP, McCone JJ, Davis MN, et al.. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2\/3 clinical trials. Liver Int. 2014, 34:707-719. 10.1111\/liv.12300","journal-title":"Liver Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02725.x","article-title":"Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1","volume":"32","author":"Manns MP","year":"2012","unstructured":"Manns MP, Markova AA, Calle Serrano B, Cornberg M. Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int. 2012, 32:27-31. 10.1111\/j.1478-3231.2011.02725.x","journal-title":"Liver Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S134818","article-title":"Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials","volume":"13","author":"Yang Y-M","year":"2017","unstructured":"Yang Y-M, Choi EJ. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Ther Clin Risk Manag. 2017, 13:477-497. 10.2147\/TCRM.S134818","journal-title":"Ther Clin Risk Manag"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.03.008","article-title":"Neurologic manifestations of hepatitis C virus infection","volume":"21","author":"Iriana S","year":"2017","unstructured":"Iriana S, Curry MP, Afdhal NH. Neurologic manifestations of hepatitis C virus infection. Clin Liver Dis. 2017, 21:535-542. 10.1016\/j.cld.2017.03.008","journal-title":"Clin Liver Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208112","article-title":"Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C","volume":"13","author":"Gallach M","year":"2018","unstructured":"Gallach M, Vergara M, da Costa JP, et al.. Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. PLoS One. 2018, 13:0208112. 10.1371\/journal.pone.0208112","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.1.18757","article-title":"The next generation of the World Health Organization\u2019s global antiretroviral guidance","volume":"16","author":"Hirnschall G","year":"2013","unstructured":"Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization\u2019s global antiretroviral guidance. J Int AIDS Soc. 2013, 16:18757. 10.7448\/IAS.16.1.18757","journal-title":"J Int AIDS Soc"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200211080-00009","article-title":"Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors","volume":"16","author":"Walker UA","year":"2002","unstructured":"Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS. 2002, 16:2165-2173. 10.1097\/00002030-200211080-00009","journal-title":"AIDS"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)90004-3","article-title":"Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity","volume":"22","author":"Kakuda TN","year":"2000","unstructured":"Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000, 22:685-708. 10.1016\/S0149-2918(00)90004-3","journal-title":"Clin Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00178.x","article-title":"Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors","volume":"5","author":"Reiss P","year":"2004","unstructured":"Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JMA. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med. 2004, 5:11-14. 10.1111\/j.1468-1293.2004.00178.x","journal-title":"HIV Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2016.25.14.9699","article-title":"Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs","volume":"25","author":"Ndakala FN","year":"2016","unstructured":"Ndakala FN, Oyugi JO, Oluka MN, Kimani J, Jablonka A, Behrens GMN. Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs. Pan Afr Med J. 2016, 25:14. 10.11604\/pamj.2016.25.14.9699","journal-title":"Pan Afr Med J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.111784","article-title":"Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria","volume":"4","author":"Agu KA","year":"2013","unstructured":"Agu KA, Oparah AC. Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspect Clin Res. 2013, 4:117-124. 10.4103\/2229-3485.111784","journal-title":"Perspect Clin Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12349","article-title":"Clinical diagnosis of sensory neuropathy in HIV patients treated with tenofovir: a 6-month follow-up study","volume":"24","author":"Pillay P","year":"2019","unstructured":"Pillay P, Wadley AL, Cherry CL, Karstaedt AS, Kamerman PR. Clinical diagnosis of sensory neuropathy in HIV patients treated with tenofovir: a 6-month follow-up study. J Peripher Nerv Syst. 2019, 24:304-313. 10.1111\/jns.12349","journal-title":"J Peripher Nerv Syst"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1177\/135965350601100214","article-title":"Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases","volume":"11","author":"Allavena C","year":"2006","unstructured":"Allavena C, Le Moal G, Michau C, Chiffoleau A, Raffi F. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir Ther. 2006, 11:263-265.","journal-title":"Antivir Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)00024-2","article-title":"Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ","volume":"3","author":"Gallant JE","year":"2016","unstructured":"Gallant JE, Daar ES, Raffi F, et al.. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ. Lancet. 2016, 3:158-165. 10.1016\/S2352-3018(16)00024-2","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-011-9939-5","article-title":"A systematic review of the psychiatric side-effects of efavirenz","volume":"15","author":"Kenedi CA","year":"2011","unstructured":"Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011, 15:1803-1818. 10.1007\/s10461-011-9939-5","journal-title":"AIDS Behav"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals","volume":"143","author":"Clifford DB","year":"2005","unstructured":"Clifford DB, Evans S, Yang Y, et al.. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005, 143:714-721. 10.7326\/0003-4819-143-10-200511150-00008","journal-title":"Ann Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1310\/P7MJ-K2WD-T1FY-AU8L","article-title":"Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse","volume":"4","author":"Juethner SN","year":"2003","unstructured":"Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials. 2003, 4:145-149. 10.1310\/P7MJ-K2WD-T1FY-AU8L","journal-title":"HIV Clin Trials"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-013-0575-0","article-title":"Whoonga: potential recreational use of HIV antiretroviral medication in South Africa","volume":"18","author":"Grelotti DJ","year":"2014","unstructured":"Grelotti DJ, Closson EF, Smit JA, et al.. Whoonga: potential recreational use of HIV antiretroviral medication in South Africa. AIDS Behav. 2014, 18:511-518. 10.1007\/s10461-013-0575-0","journal-title":"AIDS Behav"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.135","article-title":"The HIV antiretroviral drug efavirenz has LSD-like properties","volume":"38","author":"Gatch MB","year":"2013","unstructured":"Gatch MB, Kozlenkov A, Huang R-Q, et al.. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology. 2013, 38:2373-2384. 10.1038\/npp.2013.135","journal-title":"Neuropsychopharmacology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7342.879","article-title":"Drug points: Neuropsychiatric complications of nevirapine treatment","volume":"324","author":"Wise MEJ","year":"2002","unstructured":"Wise MEJ, Mistry K, Reid S. Drug points: Neuropsychiatric complications of nevirapine treatment. BMJ. 2002, 324:879. 10.1136\/bmj.324.7342.879","journal-title":"BMJ"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2009.07.009","article-title":"Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda","volume":"104","author":"van Griensven J","year":"2010","unstructured":"van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte EF, Reid T. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg. 2010, 104:148-153. 10.1016\/j.trstmh.2009.07.009","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.04.010","article-title":"Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance","volume":"95","author":"Gupta S","year":"2012","unstructured":"Gupta S, Knight AG, Losso BY, Ingram DK, Keller JN, Bruce-Keller AJ. Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance. Antiviral Res. 2012, 95:19-29. 10.1016\/j.antiviral.2012.04.010","journal-title":"Antiviral Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19764","article-title":"Potential drug-drug interactions in HIV-perinatally infected adolescents on antiretroviral therapy in Buenos Aires, Argentina","volume":"17","author":"Cordova E","year":"2014","unstructured":"Cordova E, Cecchini D, Rodriguez C. Potential drug-drug interactions in HIV-perinatally infected adolescents on antiretroviral therapy in Buenos Aires, Argentina. J Int AIDS Soc. 2014, 17:19764. 10.7448\/IAS.17.4.19764","journal-title":"J Int AIDS Soc"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-013-0683-x","article-title":"Whoonga and the abuse and diversion of antiretrovirals in Soweto, South Africa","volume":"18","author":"Rough K","year":"2014","unstructured":"Rough K, Dietrich J, Essien T, et al.. Whoonga and the abuse and diversion of antiretrovirals in Soweto, South Africa. AIDS Behav. 2014, 18:1378-1380. 10.1007\/s10461-013-0683-x","journal-title":"AIDS Behav"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1086\/422141","article-title":"Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy","volume":"39","author":"Duval X","year":"2004","unstructured":"Duval X, Journot V, Leport C, et al.. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis. 2004, 39:248-255. 10.1086\/422141","journal-title":"Clin Infect Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.19000023","article-title":"Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors","volume":"21","author":"Hoffmann C","year":"2019","unstructured":"Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019, 21:4-10. 10.24875\/AIDSRev.19000023","journal-title":"AIDS Rev"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142600","article-title":"Neurological response to cART vs. cART plus integrase inhibitor and CCR5 antagonist initiated during acute HIV","volume":"10","author":"Valcour VG","year":"2015","unstructured":"Valcour VG, Spudich SS, Sailasuta N, et al.. Neurological response to cART vs. cART plus integrase inhibitor and CCR5 antagonist initiated during acute HIV. PLoS One. 2015, 10:0142600. 10.1371\/journal.pone.0142600","journal-title":"PLoS One"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1310\/hct1505-199","article-title":"Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients","volume":"15","author":"Curtis L","year":"2014","unstructured":"Curtis L, Nichols G, Stainsby C, et al.. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials. 2014, 15:199-208. 10.1310\/hct1505-199","journal-title":"HIV Clin Trials"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"Cohen C","year":"2011","unstructured":"Cohen C, Elion R, Ruane P, et al.. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011, 25:7-12. 10.1097\/QAD.0b013e328345766f","journal-title":"AIDS"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann C","year":"2017","unstructured":"Hoffmann C, Welz T, Sabranski M, et al.. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017, 18:56-63. 10.1111\/hiv.12468","journal-title":"HIV Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2015.47.4.231","article-title":"Comparison of antiretroviral regimens: adverse effects and tolerability failure that cause regimen switching","volume":"47","author":"Kim MJ","year":"2015","unstructured":"Kim MJ, Kim S-W, Chang H-H, et al.. Comparison of antiretroviral regimens: adverse effects and tolerability failure that cause regimen switching. Infect Chemother. 2015, 47:231-238. 10.3947\/ic.2015.47.4.231","journal-title":"Infect Chemother"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.05.001","article-title":"Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes","volume":"120","author":"Llibre JM","year":"2015","unstructured":"Llibre JM, Rivero A, Rojas JF, et al.. Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. Antiviral Res. 2015, 120:79-84. 10.1016\/j.antiviral.2015.05.001","journal-title":"Antiviral Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/36966-neuropsychiatric-effects-of-antiviral-drugs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:25Z","timestamp":1707506905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/36966-neuropsychiatric-effects-of-antiviral-drugs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.9536","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,3]]}}}